IMCR
Immunocore Holdings plc
IMCR has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over IMCR overall, supported by stronger fundamentals and stronger modeled upside.
IMCR Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Under pressure | |
| Under pressure | |
| Unavailable |
IMCR's revenue is currently stable, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
IMCR PE Valuation
IMCR has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
IMCR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| Strongly improving | |
| Limited | |
| Low |
Analysts expect IMCR's losses to shrink, with revenue growing. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
IMCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.66 | -$0.09 |
| Q2 2026 | -$0.38 | +$0.02 |
| Q1 2026 | -$0.56 | -$0.13 |
| Q4 2025 | -$0.71 | +$0.31 |
| Q3 2025 | -$0.57 | +$0.41 |
| Q2 2025 | -$0.40 | +$0.70 |
| Q1 2025 | -$0.43 | +$0.82 |
| Q4 2024 | -$1.02 | +$0.21 |
IMCR is still losing money, but far less than before: $0.66 per share over the past year, against $4.12 at its worst in late 2021.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over IMCR on earnings quality, reporting a profit while its opponent remains loss making.
IMCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $102.2M | -1.4% |
| Q2 2026 | $115.9M | +18% |
| Q1 2026 | $106.7M | +14% |
| Q4 2025 | $104.5M | +24% |
| Q3 2025 | $103.7M | +29% |
| Q2 2025 | $98M | +30% |
| Q1 2025 | $93.9M | +33% |
| Q4 2024 | $84.1M | +13% |
IMCR's revenue is growing: $102M last quarter, down 1.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -13% | -6.4 points |
| Q2 2026 | -2.6% | +13 points |
| Q1 2026 | 6.8% | +11 points |
| Q4 2025 | -19% | +4.3 points |
| Q3 2025 | -6.9% | +3.7 points |
| Q2 2025 | -15% | +6.1 points |
| Q1 2025 | -3.9% | +34 points |
| Q4 2024 | -23% | +1.2 points |
IMCR's operating margin was −13% last quarter, down 6.4 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over IMCR on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over IMCR on profitability, with a higher operating margin.
IMCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $17.7M | +$22.9M |
| Q2 2026 | $15.1M | -41% |
| Q1 2026 | -$15.6M | -11455% |
| Q4 2025 | -$35.5M | -$18M |
| Q3 2025 | -$5.2M | -126% |
| Q2 2025 | $25.6M | +10% |
| Q1 2025 | $137K | +$5.2M |
| Q4 2024 | -$17.5M | +$1M |
IMCR has burned cash in most quarters: −$18M over the past year, against $3M the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over IMCR on cash generation, producing positive trailing cash flow while its opponent burns cash.
IMCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.1% | +585K shares |
| 1 year | +2.3% | +1.2M shares |
| 3 years | -4.8% | -2.6M shares |
| 5 years | +18% | +7.8M shares |
| Available history | +89% | +24.3M shares |
IMCR has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
IMCR Net Leverage
IMCR's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
IMCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 45.0 | Neutral |
| Stochastic | 30.2 | Neutral |
IMCR's weekly RSI is 45 (neutral) and its Stochastic is 30 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
IMCR PE vs Healthcare Sector
IMCR has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
IMCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $30.3 | 0.7% above |
| 20 week MA | $32.6 | 6.6% below |
| 50 week MA | $32.1 | 5% below |
| 100 week MA | $32.1 | 5.1% below |
| 200 week MA | $42.0 | 27% below |
IMCR has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 27% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over IMCR on trend strength, trading above more of its moving averages.
IMCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $43.2 | $35.4 | -18% |
| 2022 | $35.4 | $57.8 | +63% |
| 2023 | $57.8 | $68.3 | +18% |
| 2024 | $68.3 | $29.2 | -57% |
| 2025 | $29.2 | $36.1 | +24% |
| 2026 YTD | $36.1 | $30.5 | -16% |
IMCR has finished higher in three of the last five years. It's down 16% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over IMCR on returns for 2026, with the stronger performance.